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PURPOSE. To evaluate the proportion of patients in glaucoma clinics progressing at rates that
would result in visual disability within their expected lifetime.
METHODS. This retrospective study used visual field (VF) series of at least 3 years’ duration
from 3790 UK patients in glaucoma clinics calculating rates of loss for each eye using linear
regression of mean deviation (MD) over time. Residual life expectancies derived from the UK
Office of National Statistics actuarial tables for each patient were combined with these rates to
estimate predicted MDs at end of expected lifetime. The proportion of patients projected to
progress to visual impairment (MD: 14 dB or worse) or statutory blindness (MD: 22 dB or
worse) in both eyes before end of expected lifetime was calculated.
RESULTS. Only 3.0% (95% confidence interval [CI] 2.7%–3.4%) of patient eyes progressed at
faster than 1.5 dB/year (n ¼ 7149 eyes). Of those patients with both eyes followed, 5.2% (CI
4.5%–6.0%) were predicted to progress to statutory blindness, with a further 10.4% (CI 9.4%–
11.4%) reaching visual impairment in their lifetime. More than 90% (CI 85.7%–94.3%) of
patients predicted to progress to statutory blindness, had an MD worse than 6 dB in at least
one eye at presentation.
CONCLUSIONS. This modeling exercise indicates that most patients in glaucoma clinics are not at
high risk of progressing to statutory blindness. The likelihood of patients suffering
impairment in their lifetimes is linked to VF loss at presentation, which illuminates the
importance of reliably detecting significant VF defects in primary care.
Keywords: glaucoma, visual fields, perimetry, visual function, life expectancy
Treatments for glaucoma attempt to slow the rate of visualfield (VF) loss, which normally involves reducing the only
known modifiable risk factor for the condition, the IOP.1 The
main aim of treatment is to avert the threat of blindness and
ensure that a patient’s visual function, and quality of life,
remains unaffected within his or her lifetime. Once diagnosed,
all patients normally need lifelong treatment and monitoring so
that any worsening of visual impairment can be detected and
treatment can be changed accordingly. As a result, monitoring
patients with glaucoma represents a major workload for eye
services. Visual field testing (perimetry) is the only direct
method for monitoring functional change in patients, and thus,
to assess whether a treatment is succeeding in preventing
future visual impairment. Levels of VF loss can be summarized
using the mean deviation (MD) index. The MD is a weighted
average of the differences between the measured and normal
age-matched sensitivity values across the whole VF; the more
negative the MD, the worse the level of VF damage. In the
United States, statutory (legal) blindness continues to be
defined as best-corrected visual acuity of 20/200 or worse,
but also includes a definition based on VF limitation.2 In
particular, the widest diameter of the VF, in the better eye, must
subtend an angle at least 20 degrees. The US Social Security
Administration (SSA) has recently determined that automated
perimetry can be used for the latter, with an MD of 22 dB in
the better eye corresponding to the VF definition of statutory
blindness (a landmark used recently by another study).3
Many patients newly diagnosed with glaucoma are not at a
high risk of blindness. Studies based on retrospective chart
reviews have found that the proportion of patients that
progressed to blindness during follow-up ranged from approx-
imately 6% to 13%.4–6 However, these studies used data
collected on manual perimetry, were based on relatively small
numbers (all fewer than 300 patients) and were all carried out
more than 10 years ago. Other estimates for VF loss in predicted
lifetime can be extrapolated from more recently conducted
prospective studies. The Early Manifest Glaucoma Trial (EMGT)
found that the median progression rate of MD, even in patients
without treatment, was slower than 0.5 decibels (dB) per
year7; as an example, a patient with little VF damage at
diagnosis (say, 2 dB) would take 40 years to reach an MD of
22 dB at this rate of decay, assuming a linear rate of VF
deterioration (progression). Of course, 40 years is likely to
exceed most patients’ expected lifetimes when it is considered
that the onset of glaucoma is usually toward the end of patients’
lives. Obviously, there is large variation in rates of VF loss and
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faster progressing patients are at greatest risk of visual
impairment, yet the prevalence of these ‘‘fast progressors’’ in
clinical practice is unclear. Cohort studies from Canada and
California have indicated that less than approximately 5% of
patients progress at a rate of 1.5 dB/year or worse.8–10
However, results from retrospective studies, which may reflect
clinical practice more closely but are less well controlled, are
less consistent; results from the New York Progression Study
suggest that the prevalence of fast progressors ranges from 9%
to over 25% (with the use of different exclusion criteria).11–13
In addition, a recent review of clinical data from Sweden by
Heijl and colleagues14 recorded more than 15% of patients
progressing at a rate faster than 1.5 dB/year.
Taking treatment and monitoring costs into account, it is
extremely important that resources are prioritized in favor of
those patients who are at greater risk of suffering significant
visual disability in their lifetime.15 In this context, information
about rate (speed) of VF loss over a period of follow-up is
clinically useful. Recent research has emphasized the clinical
importance of this approach by recommending frequency and
pattern of VF testing required over time so as to establish
reasonable estimates of these rates.16–19 Once the rate of VF
loss has been established, a natural next step is to consider the
likelihood of a patient suffering visual disability within their
expected lifetime. Incorporating estimates of life expectancy
adjusted for age (residual life expectancy) in glaucoma care
was suggested by Wesselink et al.,20 but before now has not
been implemented. Therefore, in this study, we attempted to
estimate the proportion of patients under clinical care in
glaucoma clinics that progress at a rate quick enough to result
in serious visual impairment in their expected lifetime.
MATERIALS AND METHODS
Three separate Medisoft (Medisoft Ltd., Leeds, UK) VF
databases from glaucoma clinics in Moorfields Eye Hospital in
London, Cheltenham General Hospital Gloucestershire Eye
Unit and Queen Alexandra Hospital in Portsmouth were made
available for this retrospective study. The databases contained a
total of 402,357 anonymized VFs from 75,857 patients
recorded between 1989 and 2012. The study adhered to the
tenets of the Declaration of Helsinki, was approved by a
research governance committee of City University London and
all anonymized data were transferred to a secure computer
database. Only VFs recorded on the Humphrey Visual Field
Analyzer (HFA; Carl Zeiss Meditec, Dublin, CA) with the 24-2
test pattern, a Goldmann size III stimulus, and the SITA (SITA
Standard or SITA Fast) testing algorithm were included in the
study. Unreliable VFs, defined here to have an HFA false-
positive or false-negative score of 33% or more, or an HFA
fixation loss score of 20% or more were excluded; 29.6% of the
SITA Standard and Fast VF records were excluded from the
study owing to these reliability criteria.
This study centered on VF progression, and, to be included
in the study, one of each patient’s eyes had to have a VF series
that was at least 3 years long, with at least five VFs after
discounting the first VF in order to attempt to obviate learning
effects (improvements in results through the patient becoming
more practiced at taking the tests).21–23 The first recorded MD,
having excluded the initial VF for learning effects, is
subsequently referred to as the baseline MD, whereas the last
recorded MD in the follow-up is denoted as the final MD. The
study considered only VF data and no other clinical informa-
tion. Therefore, it was not possible to confirm whether
individuals in the database were clinically diagnosed with
glaucoma or were glaucoma suspects. Thus, the baseline VF of
each patient had to have an HFA MD or HFA pattern SD value
outside the established HFA 95% normal limits in at least one
eye. Given that individuals had measurable VF damage at
baseline and were followed regularly for at least 3 years in
these glaucoma clinics, it is reasonable to assume that the vast
majority in this study had glaucoma. Patients younger than 35
years were not included in the study.
Rates of MD loss were calculated in decibels per year (dB/y)
by using ordinary least squares regression. It was assumed that
the rate of change in MD would remain constant for the
remainder of a patient’s expected lifetime. Therefore, the MD
at expected death was calculated as the observed rate of loss
multiplied by the patient’s residual life expectancy (see Fig. 1).
It is important to use residual life expectancies to take into
account patient age rather than use population age statistics, as
the probability of dying at a particular age will not remain
constant across all ages; for instance, the probability of a 10-
year-old living to 78 is very different from an individual who
has already lived to 76. Median life expectancies, based on age
and sex, were collected from the UK Office of National
Statistics24; these were derived using the latest available
English census data (2001) and survey data to estimate
expectancies valid for the 2008 to 2010 period.
When assessing visual disability in a patient’s lifetime, it is
necessary to consider the VF loss in both eyes; a damaged VF in
one eye will not necessarily impact on the overall visual
function of a patient if the other eye remains healthy.25
Methods for classifying overall VF damage into ‘‘moderate’’ or
‘‘severe’’ abound,26–28 but few offer thresholds that have an
evidence base underpinning their link to visual impairment or
offer any practical meaning to a patient. Nevertheless, recent
results suggest that a patient with an MD less than 14 dB in
their ‘‘better’’ eye (the eye with the least-damaged VF) is highly
unlikely to satisfy the vision component of legal fitness to drive
in the UK.29 Hence, this threshold was used as a benchmark for
‘‘visual impairment’’ in the current study. A second MD
benchmark for ‘‘statutory blindness’’ equal to 22 dB, as
recommended by the US SSA,2 was also used. To be classified
as having visual impairment or statutory blindness, both
patient eyes had to reach the necessary levels of VF loss. If
patients had fewer than three VFs performed in one of their
eyes, then their baseline MDs were recorded and the eyes were
either deemed to be stable (i.e., progressing at a rate of 0 dB/y)
or progressing (at a rate of 1.5 dB/y) representing a ‘‘best-’’
and ‘‘worst-’’case scenario, respectively. In the event of no
recorded VF for the other eye, the eye was recorded as either
visually healthy for the ‘‘best-case scenario’’ or blind in the
‘‘worst-case scenario.’’ The open-source statistical environment
R30 was used for all statistical analyses.
RESULTS
The characteristics of the study sample of 3790 patients are
given in Table 1.
Figures 2A and 2B show the distribution of patient eye
follow-up times, patient residual life expectancies, and
progression rates in all eyes, respectively. It is apparent from
Figure 2B that the vast majority of eyes progressed at a rate
between 60.5 dB/y (74%–95% binomial confidence interval
[CI]: 73%–75%). A small proportion of patient eyes progressed
at a rate worse than 1 dB/y (7.5% CI: 6.9%–8.2%) and only
3.0% (CI: 2.7%–3.4%) of eyes progressed at faster than1.5 dB/
y. It is worth noting that a considerable number of eyes
recorded positive MD rates (33.3% CI: 32.2%–34.4%).
Of the 3359 patients with a VF series from both eyes (Table
2, Fig. 3; see Supplementary Material Clip S1 for an animated
version of Fig. 3), only 5.2% progressed to statutory blindness
(both eyes progressing to an MD worse than 22 dB) with a
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further 10.4% progressing to visual impairment (both eyes
progressing to an MD level of worse than 14 dB) in their
expected residual lifetime. The ‘‘best-case scenario’’ produced
similar results to those just considering eyes with two series,
but under the ‘‘worst-case scenario,’’ the number of patients at
risk of statutory blindness increased to 7.1%, and a further
11.5% were at risk of visual impairment (Table 2). Interestingly,
almost half of the patients with both eyes followed had at least
one eye with a positive rate of change (49.0% CI: 47.3–50.7).
When just patients with series in both eyes tested were
considered, 159 of the 175 patients (90.9% CI: 86.6%–95.1%)
who reached statutory blindness had an MD worse than6 dB
in at least one eye at baseline; this MD level is equivalent to
what is considered to be at least a ‘‘moderate defect’’ for one
criterion of the Hodapp-Parrish-Anderson index.26 Patients
who were predicted to progress to statutory blindness were
approximately 70% more likely to have moderate damage (MD
worse than6 dB) in at least one eye at baseline than patients
not predicted to progress to this stage (þ Likelihood Ratio: 1.7;
95% CI: 1.6–1.8). Put differently, only 1.1% (CI: 0.6%–1.6%) of
the patients who were likely diagnosed with early VF defects,
with an MD better than 6 dB in both eyes (44% of the study
FIGURE 1. A schematic illustrating the analysis conducted in this study. Visual field series from the left and right eyes of a patient were used to
estimate a linear rate of loss in each eye (dB/y). The patient’s median life expectancy was obtained from the UK Office of National Statistics,24 and
was used to predict the MD of each eye at expected time of death. In this illustration, the right eye was anticipated to progress into the statutory
blindness stage by the end of the patient’s life. However, given that the left eye is progressing less quickly and has less VF damage at the outset, this
patient would be unlikely to experience severe visual disability in the patient’s lifetime.
TABLE 1. The Demographics of Patients Analyzed in the Study
Measure
Patients With Series
in Both Eyes, n ¼ 3359
Patients With a Series
in One Eye Only, n ¼ 431
No. of patients with glaucoma (VF defects) in both eyes (%) 2212 (65.9) NA
No. of female patients (%) 1684 (50.1) 228 (52.9)
No. of patients from London (%) 3124 (93.0) 413 (95.8)
No. of patients from Cheltenham (%) 183 (5.4) 10 (2.3)
No. of patients from Portsmouth (%) 52 (1.5) 8 (1.9)
Median no. VFs recorded (IQR) 6 (5–8) 6 (5–8)
Median follow-up time (IQR) 7.1 y (5.2–9.1) 7.2 y (5.5–8.9)
Median baseline age (IQR) 65 y (56–72) 66 y (57–75)
Median final age (IQR) 71 y (62–78) 72 y (63–80)
Median residual life expectancy from final age (IQR) 16 y (11–22) 14 y (9–21)
Median baseline MD in better eye* (IQR) 2.6 dB (5.2 to 1.1) 7.0 dB (11.9 to 3.7)
Median baseline MD in worse eye* (IQR) 6.9 dB (12.5 to 3.8)
Median final MD in better eye* (IQR) 3.4 dB (6.8 to 1.3) 8.4 dB (14.6 to 4.7)
Median final MD in worse eye* (IQR) 8.7 dB (14.8 to 4.6)
Median rates of loss in better eye* (IQR) 0.12 dB/y (0.38–0.07) 0.19 dB/y (0.54–0.05)
Median rates of loss in worse eye* (IQR) 0.15 dB/y (0.46–0.08)
IQR, interquartile range (the middle 50% of ordered values ranging from the first to third quartile).
* The better eye corresponds to the eye with the better MD at the baseline VF examination.
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population), progressed to statutory blindness. Strikingly,
almost 60% (CI: 52.0%–66.4%) of patients progressing to
statutory blindness had one eye with an MD already worse than
14 dB in at least one eye at baseline.
DISCUSSION
This retrospective study of a very large number of VFs
collected in different clinics over a 23-year period has provided
a number of interesting findings. The modeling indicated that a
small proportion of patients under clinical care in glaucoma
clinics in the United Kingdom were estimated to be at high risk
of progressing to a level of statutory blindness in both eyes
during their predicted residual lifetime. The proportion of
patients predicted to be at risk of progressing to statutory
blindness in both eyes within the study was 5.2%, although this
figure may be as high as 7.1% (‘‘worst-case scenario’’)
depending on the reasons behind testing only single eyes in
some patients. These results, from the perspective of the
burden of diagnosed glaucoma, seem more optimistic than
those of previous studies. For example, Kwon et al.5 predicted
from their study that the number of patients becoming legally
blind over a follow-up of 22 years could be as high as 19%,
whereas others have also predicted higher proportions.4,6 The
different methodologies used in these studies conducted more
than a decade ago are likely to explain the different results. For
example, the previous studies did not use a modeling
approach, were based on far fewer patients, used different
definitions for legal blindness, and because they used
‘‘retrospective chart review’’ were very likely subject to
selection bias. At the same time, it is tempting to explain the
differences with the idea that modern therapies are improving
patient prognosis in glaucoma. Despite small numbers
reaching statutory blindness, it should be noted that a
significant minority of patients (approximately one in six
patients) in our study were predicted to develop VF loss that
could affect their quality of life; for example, a level of
impairment that would likely result in loss of a driving license
in the United Kingdom.29
Interestingly, the very wide distribution of rates of VF loss
shown in Figure 2B is reminiscent of similar results shown in
controlled prospective studies.7,9 However, the proportion of
eyes that are very rapidly progressing appears substantially
smaller than those of many other retrospective studies. The 3%
of eyes highlighted in our study as progressing at faster than
1.5 dB/y was in contrast to the figures from the recent
findings from the study by Heijl et al.14 in Sweden that
estimated that 15% progressed at a rate faster than 1.5 dB/y
and the New York Progression Study, which concurred that
FIGURE 2. (A) Distribution of residual life expectancies for all 3790 patients included in the study and (B) the rate of progression of MD ( dB/y) from
all 7149 eyes. The distribution of life expectancies is positively skewed as a result of the increased prevalence of glaucoma in older patients. The red
circles indicate the median (m) and other quantiles.
TABLE 2. The Proportion of Patients Likely to Suffer VF Impairment in the Course of Their Lifetime
Visual Impairment at Death
% No Impairment
(95% CI*)
% Visual Impairment
(95% CI*)
% Statutory Blindness
(95% CI*)
Including patients with a series for each eye only, n ¼ 3359 84.4 (83.2–85.6) 10.4 (9.4–11.4) 5.2 (4.5–6.0)
All patients best-case scenario, n ¼ 3790 84.9 (83.7–86.1) 10.0 (9.0–11.0) 5.1 (4.3–5.8)
All patients worst-case scenario, n ¼ 3790 81.5 (80.2–82.8) 11.5 (10.4–12.5) 7.1 (6.2–7.9)
* 95% CIs were calculated using the normal approximation of a binomial distribution.
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FIGURE 3. A series of scatterplots showing MD in left (y-axis) and right (x-axis) eyes at baseline, at the end of follow-up, through extrapolating
current rates of MD deterioration, after 10, 20, and 30 years of follow-up and at the end of expected lifetime. Both eyes in the plot had to fulfill the
original inclusion criteria. The patients are colored according to their visual disability status at expected time of death. Blue represents a patient
where at least one of the eyes has a positive slope over time, green represents progression, but no significant impairment by the end of the patient’s
lifetime, yellow represents degradation to visual impairment (14 dB or worse in both eyes), and red corresponds to statutory blindness in both eyes
(below22 dB). It is worth noting that most of the red symbols are not found in the top left corner of the baseline plot where both eyes are at an
early stage of glaucoma. See Supplementary Material Clip S1 for an animated version of this series of scatterplots.
Predicted Lifetime Visual Field Loss in Glaucoma IOVS j January 2014 j Vol. 55 j No. 1 j 106
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/932988/ on 08/24/2018
this proportion was in excess of 9%.11–13 There are several
possible reasons behind this difference. First, a sizeable
proportion of pseudoexfoliation glaucoma (associated with
faster disease deterioration7) was present in the Heijl et al.14
study, not as commonly seen in the United Kingdom. Another
possible cause is that the patients in these studies were
diagnosed with more advanced glaucoma, although it is not
really known whether those with advanced defects progress
more quickly or whether they have reached a stage of more
advanced impairment because they presented later. Our
estimates of the ‘‘fast progressor’’ prevalence was more akin
to those results from controlled clinical cohort studies.8–10
Remarkably, approximately half of all the patients sampled
experienced an ‘‘improved’’ MD in at least one eye during their
follow-up, as can be seen in Figure 3. These positive slopes can
be explained by a combination of high variability associated
with VF measurements31–33 and learning effects, which can
persist over 10 or more tests in some individuals.22,23 We
attempted to control for the latter by adopting the common
practice of removing each patient’s first recorded VF. However,
there evidently remains a substantial difficulty in measuring
rates of MD change. This has important implications for the
utility of VF testing in clinical practice. Patients who struggle
with VF testing and yield noisy measurements, or patients who
just simply get better at doing tests over time, should be
identified as soon as possible because they are using resources
that might be better used elsewhere.
Approximately 90% of those patients predicted to be at risk
of statutory blindness in their residual expected lifetime
already had noteworthy VF damage (MD worse than 6 dB)
in at least one eye at baseline (see Fig. 3). Most of these
patients had advanced impairment (60% worse than14 dB in
at least one eye) at baseline. These statistics strongly suggest
that a major contributory factor for the risk of future visual
impairment, or statutory blindness, from glaucoma is late
presentation of the disease. Other studies support this
important notion34,35 and some have explored it in more
detail, highlighting the real threat to blindness associated with
the late detection of the disease.36,37 Indeed, given this was a
study necessarily limited only to patients who were under
clinical care, these results suggest that it is the many
undiagnosed glaucoma sufferers who are at the greatest risk
of blindness. This finding raises an interesting debate about
how best to balance the use of VF resources in primary and
secondary care, especially because we have estimated that only
a minority of diagnosed patients in clinical care are in danger of
being severely impacted by their condition during their
lifetime. Specifically, it suggests that more resources should
be directed toward detecting and case finding glaucoma.
Moreover, although glaucoma is a chronic disease, our data
highlight that those affected are, of course, typically elderly
and have low residual life expectancy; the results from this
study should reinforce the need for clinicians to consider life
expectancy in their clinical management of the disease.20
Results from clinical trials and prospective studies primarily
inform clinical practice and decisions about health service
delivery. Still, retrospective analysis of very large volumes of
data collected from the everyday clinical milieu over long
periods of time can provide interesting material and informa-
tion to develop new hypotheses, as this report shows. It is
already known that volunteers for prospective studies in
glaucoma have better adherence to prescribed therapy than
those in routine medical care,38 so prospective studies and
trials may even misrepresent the routine clinical situation.
However, any retrospective study, including our own, will have
issues with missing or incomplete data, although, in this case,
this was largely offset by sheer volume of data; a significantly
larger number of VFs were used compared with other past
retrospective studies. One consequent limitation of the
retrospective study was that a small proportion of the patients
studied had complete series in only one eye (431 of 3790
patients included in the study). Unfortunately, the reasons
behind the other eye not being followed were disparate: the
eye may have either had extensive damage that rendered VF
tests uninformative, or else it may have been healthy and not
tested frequently enough to meet the inclusion criteria. We
tried to cater to both of these possibilities by providing both
the ‘‘worst-case scenario’’ and ‘‘best-case scenario’’ results.
Another issue associated with this retrospective analysis
concerns the fact that full patient records were unavailable
or not considered. As a result, analyses were based only on age,
sex, and VF data. Some of the faster-progressing patients in our
sample may have therefore had rapidly lowering MDs as a
result of concomitant age-related eye disease, principally
cataract. Also, a small minority of the study sample may not
have had glaucoma, but this is unlikely given all subjects were
monitored at specialist glaucoma clinics over at least 3 years.
Furthermore, our findings must be tempered by the possibility
that the baseline fields of the patients may not have been their
first VF assessment; for instance, patients may have been
transferred from a different clinical center.
One strength of our study is that the thresholds chosen for
visual impairment and statutory blindness have some evidence-
based justification attributed to them. Reaching levels of MD
worse than14 dB in both eyes has been shown to correspond
highly with likely no longer being legally fit to drive in the
United Kingdom, among difficulties carrying out various other
visual tasks.39–44 Furthermore,22 dB in both eyes is the point
at which one qualifies for statutory blindness in the United
States, so represents a significant milestone for patients.
However, in spite of the fact that measured sensitivities are
weighted toward fixation when calculating MDs, it is, of
course, possible to have preserved visual acuity under these
conditions; people who are diagnosed with legal blindness can
still have some useable vision. In addition, it is important to
emphasize that using the MD to define visual disability does not
appreciate the spatial distribution of VF damage, which is
important in a patient’s visual function, and ability to carry out
different tasks.39,40,42,43 For example, VF loss close to fixation
is particularly important, and eyes with this damage should be
treated more aggressively, especially because the likelihood of
further damage in the central VF is higher.45
An assumption of our analysis involves the use of a linear
rate of progression of MD over time. This may not reflect the
true nature of glaucomatous deterioration given that there is
some evidence to show patients tend to progress more quickly
at older ages, although it is unknown whether this is a result of
older age or more advanced VF deterioration.14 Nevertheless,
linear regression of MDs is commonly used in clinical practice;
the Glaucoma Progression Analysis software in the Humphrey
Field Analyzer, for instance, presents this as ‘‘one method of
Tracking Rate of Progression.’’46 Furthermore, studies suggest
that linear rates of progression for summary measures are
adequate,47 and it is important to note that a linear decline in
decibels represents an exponential decay in retinal sensitivity;
although loss of sensitivity could occur at greater than an
exponential rate, no research to date has suggested that
another type of model should be used to measure the rate of
decay of MD. In addition, previous work has shown that a
linear model of VF progression tends to provide more robust
estimates of future measurements than more complex mod-
els.48,49 This demonstrates a simple statistical principle that,
although more complex models tend to provide better fits of
existing data, linear models tend to be more useful at
predicting future change. However, it is important to be aware
that this MD regression does not imply a constant rate of
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sensitivity loss; a loss of 1 dB implies much more damage going
from5 dB to6 dB than from25 to26 dB, as a result of the
logarithmic scaling used for the measurement. It is further
noteworthy that the ‘‘future’’ forecasts based on current linear
rates of VF loss may make our estimates of future prognosis in
the patients studied overly pessimistic, as treatment is usually
intensified if a patient is in danger of progressing to visual
disability.15 On the other hand, the modeling takes no account
of concomitant eye disease, which ultimately might precipitate
levels of lifetime visual disability that are worse than those
shown in our results. A technical limitation of the calculations
is that life expectancies used were periodic and so the study
assumes that the probability of dying at a given age will remain
constant over time. It was also necessary to assume that
mortality rates are independent of glaucoma as a condition,
although this seems reasonable given results from other studies
that have specifically looked at this.50 Mortality rates could be
affected by other morbidities that may be more common in
individuals with glaucoma; it is further possible that fast
progression rates may be symptomatic of poor general health
or access to medical care, which may in turn affect life
expectancy. However, more research is required to fully
understand how life expectancy corresponds with rates of
VF loss before this can be taken into consideration.
It is important to reflect on the generalizability of our
results. First, the sample was composed only of patients from
hospital care in the United Kingdom, and it should be further
noted that the number of patients from hospitals in Ports-
mouth and Cheltenham were considerably fewer than those
from Moorfields Eye Hospital in London. Of course, there is no
guarantee that patients were treated equivalently across
hospitals and thus our results mostly reflect observations in
Moorfields Eye Hospital. Results are not directly applicable to
countries with different demographics and different health
care systems. On the other hand, London is a cosmopolitan
city; the 2011 Census reported that more than one-quarter of
the population of London did not identify themselves as
British,51 so it could be postulated that there is a fair amount of
diversity among the patients, although the lack of clinical data
makes it impossible to determine this for certain. Another issue
with the study, particularly when focusing on the finding that
worse VF loss at baseline is associated with a higher risk of
blindness, is that it is assumed that various factors that may
have an effect on end state of disease, such as type of glaucoma
and race of patient, were relatively uniform throughout the
study. Unfortunately, it was not possible to control for these
variables, but it is assumed, given the quantity of the data, that
the findings overall represent a reasonable population esti-
mate.
In conclusion, the main result from this modeling exercise
suggests that most glaucoma patients under clinical care are
not in considerable danger of suffering significant visual
disability in their lifetime. This report certainly indicates that
the great majority of patients who are followed in glaucoma
clinics in the United Kingdom have stable VFs. There is,
however, enormous variability in rates of VF loss and also in
levels of VF damage at presentation. Patients who are in danger
of significant VF impairment in their lifetime generally present
with more severe VF damage and this may indicate that more
resources should be concentrated toward detecting disease
before it progresses beyond early damage. We hope that these
results can inform the design of better health service delivery
and suggest studies that should investigate improved allocation
of VF testing resources.15 Furthermore, the results from this
study illuminate very clearly the importance of reliably
detecting significant VF defects, and other features of
glaucoma, in primary care.37
Acknowledgments
Supported in part by the UK National Institute for Health Research
Health Services & Delivery Research Programme (Project 10/2000/
68).
Disclosure: L.J. Saunders, None; R.A. Russell, None; J.F.
Kirwan, None; A.I. McNaught, None; D.P. Crabb, None
References
1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B,
Hussein M. Reduction of intraocular pressure and glaucoma
progression—results from the early manifest glaucoma trial.
Arch Ophthalmol. 2002;120:1268–1279.
2. US Social Security Administration. Disability evaluation under
Social Security. Available at: http://www.ssa.gov/disability/
professionals/bluebook/2.00-SpecialSensesandSpeech-Adult.
htm#203. Accessed January 21, 2013.
3. Heijl A, Aspberg J, Bengtsson B. The effect of different criteria
on the number of patients blind from open-angle glaucoma.
BMC Ophthalmol. 2011;11:31.
4. Chen PP. Blindness in patients with treated open-angle
glaucoma. Ophthalmology. 2003;110:726–733.
5. Kwon YH, Kim C, Zimmerman MB, Alward WLM, Hayreh SS.
Rate of visual field loss and long-term visual outcome in
primary open-angle glaucoma. Am J Ophthalmol. 2001;132:
47–56.
6. Hattenhauer MG, Johnson DH, Ing HH, et al. The probability of
blindness from open-angle glaucoma. Ophthalmology. 1998;
105:2099–2104.
7. Heijl A, Bengtsson B, Hyman L, Leske MC. Natural history of
open-angle glaucoma. Ophthalmology. 2009;116:2271–2276.
8. Medeiros FA, Zangwill LM, Mansouri K, Lisboa R, Tafreshi A,
Weinreb RN. Incorporating risk factors to improve the
assessment of rates of glaucomatous progression. Invest
Ophthalmol Vis Sci. 2012;53:2199–2207.
9. Chauhan BC, Mikelberg FS, Artes PH, et al. Canadian glaucoma
study: 3. Impact of risk factors and intraocular pressure
reduction on the rates of visual field change. Arch Ophthal-
mol. 2010;218:1249–1255.
10. Reis ASC, Artes PH, Belliveau AC, et al. Rates of change in the
visual field and optic disc in patients with distinct patterns of
glaucomatous optic disc damage. Ophthalmology. 2012;119:
294–303.
11. De Moraes CG, Prata TS, Tello C, Ritch R, Liebmann JM.
Glaucoma with early visual field loss affecting both hemifields
and the risk of disease progression. Arch Ophthalmol. 2009;
127:1129–1134.
12. Prata TS, De Moraes CG, Teng CC, Tello C, Ritch R, Liebmann
JM. Factors affecting rates of visual field progression in
glaucoma patients with optic disc hemorrhage. Ophthalmol-
ogy. 2010;117:24–29.
13. Teng CC, De Moraes CG, Prata TS, Tello C, Ritch R, Liebmann
JM. b-Zone parapapillary atrophy and the velocity of glaucoma
progression. Ophthalmology. 2010;117:909–915.
14. Heijl A, Buchholz P, Norrgren G, Bengtsson B. Rates of visual
field progression in clinical glaucoma care. Acta Ophthalmol
Scand. 2012;91:406–412.
15. Heijl A. The times they are a-changin’: Time to change
glaucoma management. Acta Ophthalmol Scand. 2013;91:92–
99.
16. Chauhan BC, Garway-Heath DF, Goni FJ, et al. Practical
recommendations for measuring rates of visual field change
in glaucoma. Br J Ophthalmol. 2008;92:569–573.
17. European Glaucoma Society. European Glaucoma Society
Guidelines (2008): Terminology and Guidelines for Glauco-
ma. Savona, Italy: Editrice DOGMA; 2008;117–153.
Predicted Lifetime Visual Field Loss in Glaucoma IOVS j January 2014 j Vol. 55 j No. 1 j 108
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/932988/ on 08/24/2018
18. Crabb DP, Garway-Heath DF. Intervals between visual field
tests when monitoring the glaucomatous patient: wait and
see. Invest Ophthalmol Vis Sci. 2012;53:2770–2776.
19. Jansonius NM. On the accuracy of measuring rates of visual
field change in glaucoma. Br J Ophthalmol. 2010;94:1404–
1405.
20. Wesselink C, Stoutenbeek R, Jansonius NM. Incorporating life
expectancy in glaucoma care. Eye. 2011;25:1575–1580.
21. Wild JM, Dengler-Harles M, Searle AET, O’Neill EC, Crews SJ.
The influence of the learning effect on automated perimetry in
patients with suspected glaucoma. Acta Ophthalmol Scand.
1989;67:537–545.
22. Heijl A, Lindgren G, Olsson J. The effect of perimetric
experience in normal subjects. Arch Ophthalmol. 1989;107:
81–86.
23. Heijl A, Bengtsson B. The effect of perimetric experience in
patients with glaucoma. Arch Ophthalmol. 1996;114:19–22.
24. Office of National Statistics. England, Interim Life Tables,
1980–82 to 2008–10. Available at: http://ons.gov.uk/ons/rel/
lifetables/interim-life-tables/2008-2010/rft-ilt-eng-2008-10.xls.
Accessed August 31, 2012.
25. Jampel HD, Friedman DS, Quigley HA, Miller R. Correlation of
the binocular visual field with patient assessment of vision.
Invest Ophthalmol Vis Sci. 2002;43:1059–1067.
26. Hodapp E, Parrish RKI, Anderson DR. Clinical Decisions in
Glaucoma. St Louis: The CV Mosby Co.; 1993.
27. Brusini P, Filacorda S. Enhanced Glaucoma Staging System
(GSS 2) for classifying functional damage in glaucoma. J
Glaucoma. 2006;15:40–6.
28. Susanna R Jr, Vessani RM. Staging glaucoma patient: why and
how? Open Ophthalmol J. 2009;3:59–64.
29. Saunders LJ, Russell RA, Crabb DP. Practical landmarks for
visual field disability in glaucoma. Br J Ophthalmol. 2012;96:
1185–1189.
30. R Development Core Team. R: A Language and Environment
for Statistical Computing. Vienna, Austria: R Foundation for
Statistical Computing; 2013. Available at: http://www.
R-project.org.
31. Heijl A, Lindgren G, Olsson J. Normal variability of static
perimetric threshold values across the central visual field.
Arch Ophthalmol. 1987;105:1544–1549.
32. Turpin A, McKendrick AM. What reduction in standard
automated perimetry variability would improve the detection
of visual field progression? Invest Ophthalmol Vis Sci. 2011;
52:3237–3245.
33. Russell RA, Crabb DP, Malik R, Garway-Heath DF. The
relationship between variability and sensitivity in large-scale
longitudinal visual field data. Invest Ophthalmol Vis Sci. 2012;
53:5985–5990.
34. Grant WM, Burke JFJ. Why do some people go blind from
glaucoma? Ophthalmology. 1982;89:991–998.
35. Oliver JE, Hattenhauer MG, Herman D, et al. Blindness and
glaucoma: a comparison of patients progressing to blindness
from glaucoma with patients maintaining vision. Am J
Ophthalmol. 2002;133:764–772.
36. Kotecha A, Fernandes S, Bunce C, Franks WA. Avoidable sight
loss from glaucoma: is it unavoidable? Br J Ophthalmol. 2012;
96:816–820.
37. Henson DB, Thampy R. Preventing blindness from glauco-
ma—better screening with existing tests should be the
priority. BMJ. 2005;331:120–121.
38. Henson DB, Shambhu S. Relative risk of progressive glau-
comatous visual field loss in patients enrolled and not enrolled
in a prospective longitudinal study. Arch Ophthalmol. 2006;
124:1405–1408.
39. Kooijman AC, Brouwer WH, Coeckelbergh TRM, et al.
Compensatory viewing training improves practical fitness to
drive of subjects with impaired vision. Vis Impair Res. 2004;6:
1–27.
40. Kotecha A, O’Leary N, Melmoth D, Grant S, Crabb DP. The
functional consequences of glaucoma for eye-hand coordina-
tion. Invest Ophthalmol Vis Sci. 2009;50:203–213.
41. Smith ND, Crabb DP, Garway-Heath DF. An exploratory study
of visual search performance in glaucoma. Ophthalmic
Physiol Opt. 2011;31:225–232.
42. Black AA, Wood JM, Lovie-Kitchin JE. Inferior field loss
increases rate of falls in older adults with glaucoma. Optom
Vis Sci. 2011;88:1275–1282.
43. Tabrett DR, Lathan K. Important areas of the central binocular
visual field for daily functioning in the visually impaired.
Ophthalmic Physiol Opt. 2012;32:156–163.
44. Glen FC, Crabb DP, Smith ND, Burton R, Garway-Heath DF. Do
patients with glaucoma have difficulty recognising faces?
Invest Ophthalmol Vis Sci. 2012;53:3629–3637.
45. Membrey WL, Poinoosaumy DP, Bunce C, Fitzke FW, Hitchings
RA. Comparison of visual field progression in patients with
normal pressure glaucoma between eyes with and without
visual field loss that threatens fixation. Br J Ophthalmol. 2000;
84:1154–1158.
46. Carl Zeiss Meditec, Inc. Humphrey Glaucoma Progression
Analysis. (GPA) Software—An advanced approach to monitor-
ing disease progression. Available at: http://www.zeiss.de/
C125679E00525939/EmbedTitel Intern/OFS_White_
Paper16_eng/$File/OFS_whitepaper16_eng.pdf. Accessed Oc-
tober 6, 2013.
47. Bengtsson B, Patella VM, Heijl A. Prediction of glaucomatous
visual field loss by extrapolation of linear trends. Arch
Ophthalmol. 2009;127:1610–1615.
48. McNaught AI, Crabb DP, Fitzke FW, Hitchings RA. Modelling
series of visual fields to detect progression in normal-tension
glaucoma. Graefes Arch Clin Exp Ophthalmol. 1995;233:750–
755.
49. Bryan SR, Vermeer KA, Eilers PHC, Lemij HG, Lesaffre EMEH.
Robust and censored modeling and prediction of progression
in glaucomatous visual fields. Invest Ophthalmol Vis Sci. 2013;
54:6694–6700.
50. Grodum K, Heijl A, Bengtsson B. Glaucoma and mortality.
Graefes Arch Clin Exp Ophthalmol. 2004;242:397–401.
51. Office of National Statistics. Ethnicity and national identity in
England and Wales 2011. Available at: http://www.ons.gov.uk/
ons/dcp171776_290558.pdf. Accessed November 3, 2013.
Predicted Lifetime Visual Field Loss in Glaucoma IOVS j January 2014 j Vol. 55 j No. 1 j 109
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/932988/ on 08/24/2018
